Inactive Instrument

PharmaCyte Biotech, Inc. Stock price Other OTC

Equities

PMCB

US71715X1046

Pharmaceuticals

Sales 2022 - Sales 2023 - Capitalization 50.93M
Net income 2022 -4M Net income 2023 -4M EV / Sales 2022 -
Net cash position 2022 85.4M Net cash position 2023 68.04M EV / Sales 2023 -
P/E ratio 2022
-8.53 x
P/E ratio 2023
-13.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 35.93%
More Fundamentals * Assessed data
Dynamic Chart
PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors CI
Femasys Inc. announces tranche update CI
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc. CI
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023. CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023. CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023 CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on May 11, 2023. CI
PharmaCyte Biotech, Inc.'s Equity Buyback announced on May 11, 2023, has closed with 8,085,879 shares, representing 48.15% for $26.46 million. CI
PharmaCyte Biotech, Inc. announces an Equity Buyback for 7,750,000 shares, for $25.19 million. CI
PharmaCyte Biotech, Inc authorizes a Buyback Plan. CI
PharmaCyte Biotech, Inc. announced that it has received $35 million in funding CI
More news
Managers TitleAgeSince
Chief Executive Officer 54 22-08-14
Director of Finance/CFO 66 14-12-31
Chief Tech/Sci/R&D Officer - 20-08-09
Members of the board TitleAgeSince
Director/Board Member 64 22-11-13
Chief Executive Officer 54 22-08-14
Director/Board Member 65 22-12-27
More insiders
PharmaCyte Biotech, Inc. is a biotechnology company. The Company is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. The Company’s product candidate is referred to as CypCaps. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also developing therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
More about the company
  1. Stock
  2. Equities
  3. Stock PharmaCyte Biotech, Inc.
  4. Stock PharmaCyte Biotech, Inc. - Other OTC